Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ropeginterferon alfa-2b versus anagrelide as second-line therapy for essential thrombocythemia in Japan
jRCT2080225218Phase 3Completed
- Sponsor
- PharmaEssentia
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in thrombocythemia comparing Ropeginterferon alfa-2b arm with Anagrelide arm (2 arms). Started Jun 2020; status: completed.
02
Drugs
ropeginterferon alfa-2banagrelide
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on jRCT2080225218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225218.